India, Dec. 24 -- image credit- freepik

Bioeq AG, a Swiss biopharmaceutical company, and Ahmedabad-based Zydus Lifesciences hasannounced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialisation of Bioeq's Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO(R), an interchangeable biosimilar of Lucentis(R)(Ranibizumab) for the US market.Lucentis(R)is a registered trademark of Genentech, Inc., a member of the Roche Group.

The Biologics License Application (BLA) for NUFYMCO(R)has been approved by US Food and Drug Administration (USFDA) on December 18, 2025. This transaction marks an expansion of Zydus' US...